GlobeImmune, Inc. (GBIM) financial statements (2020 and earlier)

Company profile

Business Address 1450 INFINITE DRIVE
LOUISVILLE, CO 80027
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1017
Cash and cash equivalents 1017
Other current assets 11
Total current assets: 1118
Noncurrent Assets
Property, plant and equipment 00
Other noncurrent assets 0 
Other undisclosed noncurrent assets  0
Total noncurrent assets: 01
TOTAL ASSETS: 1218
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 12
Accounts payable 01
Accrued liabilities 11
Employee-related liabilities  1
Deferred revenue and credits 33
Other undisclosed current liabilities  (1)
Total current liabilities: 45
Noncurrent Liabilities
Liabilities, other than long-term debt 48
Deferred revenue and credits 47
Other liabilities 00
Total noncurrent liabilities: 48
Total liabilities: 913
Stockholders' equity
Stockholders' equity attributable to parent 36
Common stock 00
Additional paid in capital 228228
Accumulated deficit (225)(223)
Total stockholders' equity: 36
TOTAL LIABILITIES AND EQUITY: 1218

Income statement (P&L) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
Revenues
(Revenue, Net)
 66
Cost of revenue
(Cost of Goods and Services Sold)
 (2)(5)
Gross profit: 41
Operating expenses (9)(12)
Other undisclosed operating income 25
Operating loss: (3)(6)
Nonoperating expense  (2)
Investment income, nonoperating  (2)
Interest and debt expense  (9)
Net loss attributable to parent: (3)(16)
Preferred stock dividends and other adjustments  (7)
Net loss available to common stockholders, diluted: (3)(23)

Comprehensive Income ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
Net loss: (3)(16)
Comprehensive loss, net of tax, attributable to parent: (3)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: